The Study
Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.
This study tested which drugs work better on cancer cells that are missing a specific gene part, but only in petri dishes and tiny lab-grown tissue bits. It doesn't prove these drugs will work in real people—it just shows a pattern that might be worth testing further.
Analysis score
Maximum 58 for a case-control study.
Where the score came from
Scientists found that when a certain gene group (9p21) is missing in cancer cells, some chemotherapy drugs work much better — like a lock that only opens with the right key.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 540 / 100
Quality score
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means patients with this specific gene loss might respond dramatically better to these drug combinations, offering a targeted treatment option.
- 2Cytarabine and methotrexate killed 9p21-deficient cancer cells much better than normal cells; adding two other drugs (MRTX1719 and AG-270) made the effect even stronger.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
NPJ precision oncology
Year
2026
Authors
R. Bevilacqua, P. Gasperini, T. Cantore, C. Macedo-Silva, M. Pancher, Martina Radić, Haiyan Yue, O. Quaini, T. Fedrizzi, Pamela Gatto, R. Seiler, Bernhard Kiss, V. Adami, F. Lorenzin, M. Kruithof-de Julio, B. Faltas, F. Demichelis
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.